BRIDGEWAY CAPITAL MANAGEMENT, LLC - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 49 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
BRIDGEWAY CAPITAL MANAGEMENT, LLC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2018$265,000
+55.0%
52,5000.0%0.00%
+50.0%
Q2 2018$171,000
-10.0%
52,5000.0%0.00%0.0%
Q1 2018$190,000
+77.6%
52,5000.0%0.00%
+100.0%
Q4 2017$107,00052,5000.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q4 2018
NameSharesValueWeighting ↓
Novo Holdings A/S 1,280,185$9,755,0001.01%
Cormorant Asset Management, LP 201,000$1,532,0000.24%
PUTNAM INVESTMENTS LLC 575,692$4,386,0000.01%
Alyeska Investment Group, L.P. 114,113$870,0000.01%
VANGUARD GROUP INC 4,355,424$131,473,0000.01%
BLACKROCK ADVISORS LLC 463,200$3,530,0000.00%
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 26,100$199,000,0000.00%
Ironwood Financial, llc 870$7,0000.00%
PANAGORA ASSET MANAGEMENT INC 24,293$185,0000.00%
Sonora Investment Management, LLC 500$3,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders